53292-90-3

Usage

Chemical Properties

White powder

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 

Downstream Products

• 400898-94-4 trans-(4-formylcyclohexyl)methylcarbamic acid tert-butyl ester 
• 400899-08-3 tert-butyl ((1r,4r)-4-(hydroxymethyl)cyclohexyl)(methyl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 615568-05-3 C₂₁H₂₈N₄O₄ 
• 643067-91-8 1,1-dimethylethyl [trans-4-(aminocarbonyl)cyclohexyl]carbamate 
• 791775-31-0 (1r,4r)-4-aminocyclohexane-1-carboxamide 
• 1021920-37-5 (1r,4r)-4-(3-amino-6-bromopyrazin-2-ylamino)cyclohexanecarboxamide 
• 1021919-78-7 (1r,4r)-4-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-1-yl)cyclohexane carboxamide 

Relevant academic research and scientific papers

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

Preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof

The invention provides a preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and an intermediate thereof. The preparation method is characterized by comprising the following steps of 4 - oxocyclohexane carboxylic ester and chiral ligand reagent tert-butyl sulfinamide as a raw material, reducing amination to obtain trans -4 -tert-butyl sulfinyl sulfenamide cyclohexane carboxylic acid ester by virtue of chiral ligand reagent tert-butyl sulfinamide and 4 - 95% -oxocyclohexane carboxylic ester, and is stable in basic conditions and easy to leave under an acidic condition. Reaction conditions are mild, operation is simple and convenient, yield is high, and industrial production is easy.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat

Preparation method of trans-4-N-Bocaminocyclohexylamine carboxylic acid

The invention discloses a preparation method of trans-4-N-Bocaminocyclohexylamine carboxylic acid, and belongs to the technical field of organic synthesis. 4-oxocyclohexane carboxylic acid triphenyl methanol ester is taken as the raw material, and the pro

Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains

A structure-activity relationship study of potent TIQ15-derived CXCR4 antagonists is reported. In this investigation, the TIQ15 side-chain was constrained to improve its drug properties. The cyclohexylamino congener 15a was found to be a potent CXCR4 inhi

ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS

Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an eff

BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE

Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.